Amphiregulin shRNA Plasmid (h) from Santa Cruz Biotechnology, Inc.

Product Specs
ItemAmphiregulin shRNA Plasmid (h)
CompanySanta Cruz Biotechnology, Inc.
Price $592.00Supplier Page View Company Product Page
Catalog Numbersc-39412-SH
NCBI Gene AliasesAR, AREGB, CRDGF, SDGF
NCBI Full Gene Nameamphiregulin
Specieshuman
TypeshRNA Plasmid
RNA TypeshRNA Clones
Quantity20 µg
Vector Type (Standardized)Lentiviral

Add to Compare List

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell CarcinomaCancer ResearchJuly 15, 2025Jung Hyun Um, Yueyuan Zheng, Qiong Mao, Chehyun Nam, Hua Zhao, Yoon Woo Koh, Su-Jin Shin, Young Min Park, De-Chen Lintransfection reagent BioT (Bioland Scientific, Cat#B01–01) or shRNA viral particles (Santa Cruz Biotechnology, Cat#sc-39412-SH). Recombinant AREG protein (R&D Biotechne, Cat#262-AR-100/CF) and Afatinib (Medchem Express, Cat#HY-10261)

(2) Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell CarcinomaCancer ResJuly 15, 2025Jung Hyun Um, Yueyuan Zheng, Qiong Mao, Chehyun Nam, Hua Zhao, Yoon Woo Koh, Su-Jin Shin, Young Min Park, De-Chen Lintransfection reagent BioT (Bioland Scientific, Cat#B01–01) or shRNA viral particles (Santa Cruz Biotechnology, Cat#sc-39412-SH). Recombinant AREG protein (R&D Biotechne, Cat#262-AR-100/CF) and Afatinib (Medchem Express, Cat#HY-10261)

(3) Genomic and single-cell characterization of patient-derived tumor organoid models of head and neck squamous cell carcinomabioRxiv : the preprint server for biologyJuly 2, 2024Um JH, Zheng Y, Mao Q, Nam C, Zhao H, Koh YW, Shin SJ, Park YM, Lin DC.transfected two different siRNAs (IDT technologies) or shRNA viral particles (Santa Cruz Biotechnology, Cat#sc-39412-SH) using transfection reagent BioT (Bioland Scientific, Cat#B01–01). To increase AREG protein level in

(4) Tricellular tight junction protein LSR/angulin-1 contributes to the epithelial barrier and malignancy in human pancreatic cancer cell lineHistochemistry and cell biologyJanuary 1, 2020Kyuno T, Kyuno D, Kohno T, Konno T, Kikuchi S, Arimoto C, Yamaguchi H, Imamura M, Kimura Y, Kondoh M, et al.

(5) Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathwayScientific reportsJune 9, 2017Taverna S, Pucci M, Giallombardo M, Di Bella MA, Santarpia M, Reclusa P, Gil-Bazo I, Rolfo C, Alessandro R.Amphiregulin with shRNA Plasmid in CRL-2868 cells Stable transfection of Amphiregulin shRNA Plasmid sc-39412-SH (Santa Cruz Biotechnology, Inc.) in CRL 2868 cells was carried out according to the suggestions from

(6) Amphiregulin as a Novel Resistance Factor for Amrubicin in Lung Cancer CellsAnticancer researchMay 1, 2017Tokunaga S, Nagano T, Kobayashi K, Katsurada M, Nakata K, Yamamoto M, Tachihara M, Kamiryo H, Yokozaki H, Nishimura Y.

(7) Loss of tricellular tight junction protein LSR promotes cell invasion and migration via upregulation of TEAD1/AREG in human endometrial cancerScientific reportsJanuary 10, 2017Shimada H, Abe S, Kohno T, Satohisa S, Konno T, Takahashi S, Hatakeyama T, Arimoto C, Kakuki T, Kaneko Y, et al.

(8) MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulinOncotargetApril 26, 2016Wen Y, Li H, Zeng Y, Wen W, Pendleton KP, Lui VW, Egloff AM, Grandis JR.

(9) The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanismInternational journal of cancerJune 1, 2014Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A.

(10) Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the boneMolecular cancer research : MCROctober 1, 2009Gilmore JL, Gonterman RM, Menon K, Lorch G, Riese DJ 2nd, Robling A, Foley J.

Be the First to Write a Review!